OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial
Run Dong, Li Jiang, Ting Yang, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 3
Open Access | Times Cited: 8
Run Dong, Li Jiang, Ting Yang, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 3
Open Access | Times Cited: 8
Showing 8 citing articles:
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
Caroline Hirsch, Yun Soo Park, Vanessa Piechotta, et al.
Cochrane library (2022) Vol. 2022, Iss. 6
Open Access | Times Cited: 38
Caroline Hirsch, Yun Soo Park, Vanessa Piechotta, et al.
Cochrane library (2022) Vol. 2022, Iss. 6
Open Access | Times Cited: 38
Single-cell technology for cell-based drug delivery and pharmaceutical research
Huihui Hu, Yunlong Fan, Jiawen Wang, et al.
Journal of Controlled Release (2025) Vol. 381, pp. 113587-113587
Closed Access
Huihui Hu, Yunlong Fan, Jiawen Wang, et al.
Journal of Controlled Release (2025) Vol. 381, pp. 113587-113587
Closed Access
Research and development of Chinese anti-COVID-19 drugs
Xiwei Ji, Xiangrui Meng, Xiao Zhu, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 12, pp. 4271-4286
Open Access | Times Cited: 19
Xiwei Ji, Xiangrui Meng, Xiao Zhu, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 12, pp. 4271-4286
Open Access | Times Cited: 19
Clinical efficacy and safety of SARS-CoV-2-neutralizing monoclonal antibody in patients with COVID-19: A living systematic review and meta-analysis
Su‐Yeon Yu, Miyoung Choi, Chelim Cheong, et al.
Journal of Microbiology Immunology and Infection (2023) Vol. 56, Iss. 5, pp. 909-920
Open Access | Times Cited: 8
Su‐Yeon Yu, Miyoung Choi, Chelim Cheong, et al.
Journal of Microbiology Immunology and Infection (2023) Vol. 56, Iss. 5, pp. 909-920
Open Access | Times Cited: 8
Better design leads to better results – Importance of virological outcome design in clinical trials for antiviral treatment of coronavirus disease 2019
Getu Zhaori, Lu Lu, Chunyan Liu, et al.
Pediatric Investigation (2023) Vol. 7, Iss. 1, pp. 1-5
Open Access | Times Cited: 3
Getu Zhaori, Lu Lu, Chunyan Liu, et al.
Pediatric Investigation (2023) Vol. 7, Iss. 1, pp. 1-5
Open Access | Times Cited: 3
Effects of the COVID-19 pandemic: new approaches for accelerated delivery of gene to first-in-human CMC data for recombinant proteins
Hervé Broly, Jonathan Souquet, Alain Beck
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Hervé Broly, Jonathan Souquet, Alain Beck
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Monoclonal Antibodies in Hospitalised Patients with COVID-19: The Role of SARS-COV-2 Serostatus in an Evolving Pandemic
F. Raffi, Robert Gottlieb
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 3, pp. 735-747
Open Access | Times Cited: 2
F. Raffi, Robert Gottlieb
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 3, pp. 735-747
Open Access | Times Cited: 2
Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials
Ana Flávia Amorim, Joselin Valeska Martinez-Sobalvarro, Larissa Helena Torres, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 12, pp. 9573-9589
Closed Access
Ana Flávia Amorim, Joselin Valeska Martinez-Sobalvarro, Larissa Helena Torres, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 12, pp. 9573-9589
Closed Access
